Summary of Significant Accounting Policies - Summary of Revenue by Category (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022		Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Revenue	$ 271,893		$ 243,920	$ 305,463
PGS
Disaggregation Of Revenue [Line Items]
Revenue	202,681		197,525	271,639
PGS | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	189,703		191,066	263,679
PGS | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	12,978		6,459	7,960
Telehealth
Disaggregation Of Revenue [Line Items]
Revenue	19,207	[1]
Telehealth | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	15,299	[1]
Telehealth | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	3,908	[1]
Consumer services
Disaggregation Of Revenue [Line Items]
Revenue	221,888		197,525	271,639
Consumer services | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	205,002		191,066	263,679
Consumer services | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	16,886		6,459	7,960
Research Services
Disaggregation Of Revenue [Line Items]
Revenue	50,005		46,341	28,268
Research Services | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	0		0	0
Research Services | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue
Therapeutics
Disaggregation Of Revenue [Line Items]
Revenue			54	5,556
Therapeutics | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Revenue			54	5,556
Therapeutics | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue
Service
Disaggregation Of Revenue [Line Items]
Revenue	271,893		243,920	305,463
Service | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	205,002		191,120	269,235
Service | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 66,891		$ 52,800	$ 36,228
Product Concentration Risk [Member] | Revenue Benchmark [Member] | PGS
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	75.00%		81.00%	89.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | PGS | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	70.00%		78.00%	86.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | PGS | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	5.00%		3.00%	3.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Telehealth
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	7.00%	[1]	0.00%	0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Telehealth | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	6.00%	[1]	0.00%	0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Telehealth | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	1.00%	[1]	0.00%	0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	82.00%		81.00%	89.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	76.00%		78.00%	86.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	6.00%		3.00%	3.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	18.00%		19.00%	9.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	0.00%		0.00%	0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	18.00%		19.00%	9.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Therapeutics
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	0.00%		0.00%	2.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Therapeutics | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	0.00%		0.00%	2.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Therapeutics | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	0.00%		0.00%	0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	100.00%		100.00%	100.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service | Point in time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	76.00%		78.00%	88.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service | Over Time [Member]
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	24.00%		22.00%	12.00%

[1] For the year ended March 31, 2022, telehealth revenue included the five month period from the close of the acquisition of Lemonaid Health on November 1, 2021 through March 31, 2022.